Search Results - "Journal of clinical oncology"

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update by Schneider, Bryan J, Naidoo, Jarushka, Santomasso, Bianca D, Lacchetti, Christina, Adkins, Sherry, Anadkat, Milan, Atkins, Michael B, Brassil, Kelly J, Caterino, Jeffrey M, Chau, Ian, Davies, Marianne J, Ernstoff, Marc S, Fecher, Leslie, Ghosh, Monalisa, Jaiyesimi, Ishmael, Mammen, Jennifer S, Naing, Aung, Nastoupil, Loretta J, Phillips, Tanyanika, Porter, Laura D, Reichner, Cristina A, Seigel, Carole, Song, Jung-Min, Spira, Alexander, Suarez-Almazor, Maria, Swami, Umang, Thompson, John A, Vikas, Praveen, Wang, Yinghong, Weber, Jeffrey S, Funchain, Pauline, Bollin, Kathryn

“…To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with…”
Get full text

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer by Spigel, David R, Faivre-Finn, Corinne, Gray, Jhanelle E, Vicente, David, Planchard, David, Paz-Ares, Luis, Vansteenkiste, Johan F, Garassino, Marina C, Hui, Rina, Quantin, Xavier, Rimner, Andreas, Wu, Yi-Long, Özgüroğlu, Mustafa, Lee, Ki H, Kato, Terufumi, de Wit, Maike, Kurata, Takayasu, Reck, Martin, Cho, Byoung C, Senan, Suresh, Naidoo, Jarushka, Mann, Helen, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J

“…The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression…”
Get full text

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study by Marabelle, Aurelien, Le, Dung T, Ascierto, Paolo A, Di Giacomo, Anna Maria, De Jesus-Acosta, Ana, Delord, Jean-Pierre, Geva, Ravit, Gottfried, Maya, Penel, Nicolas, Hansen, Aaron R, Piha-Paul, Sarina A, Doi, Toshihiko, Gao, Bo, Chung, Hyun Cheol, Lopez-Martin, Jose, Bang, Yung-Jue, Frommer, Ronnie Shapira, Shah, Manisha, Ghori, Razi, Joe, Andrew K, Pruitt, Scott K, Diaz, Jr, Luis A

“…Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic…”
Get full text

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma by Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean-Jacques, Rutkowski, Piotr, Lao, Christopher D, Cowey, C Lance, Schadendorf, Dirk, Wagstaff, John, Dummer, Reinhard, Ferrucci, Pier Francesco, Smylie, Michael, Butler, Marcus O, Hill, Andrew, Márquez-Rodas, Ivan, Haanen, John B A G, Guidoboni, Massimo, Maio, Michele, Schöffski, Patrick, Carlino, Matteo S, Lebbé, Céleste, McArthur, Grant, Ascierto, Paolo A, Daniels, Gregory A, Long, Georgina V, Bas, Tuba, Ritchings, Corey, Larkin, James, Hodi, F Stephen

“…In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus…”
Get full text

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy by Garcia-Aguilar, Julio, Patil, Sujata, Gollub, Marc J, Kim, Jin K, Yuval, Jonathan B, Thompson, Hannah M, Verheij, Floris S, Omer, Dana M, Lee, Meghan, Dunne, Richard F, Marcet, Jorge, Cataldo, Peter, Polite, Blase, Herzig, Daniel O, Liska, David, Oommen, Samuel, Friel, Charles M, Ternent, Charles, Coveler, Andrew L, Hunt, Steven, Gregory, Anita, Varma, Madhulika G, Bello, Brian L, Carmichael, Joseph C, Krauss, John, Gleisner, Ana, Paty, Philip B, Weiser, Martin R, Nash, Garrett M, Pappou, Emmanouil, Guillem, José G, Temple, Larissa, Wei, Iris H, Widmar, Maria, Lin, Sabrina, Segal, Neil H, Cercek, Andrea, Yaeger, Rona, Smith, J Joshua, Goodman, Karyn A, Wu, Abraham J, Saltz, Leonard B

“…Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total…”
Get full text

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma by Finn, Richard S, Ikeda, Masafumi, Zhu, Andrew X, Sung, Max W, Baron, Ari D, Kudo, Masatoshi, Okusaka, Takuji, Kobayashi, Masahiro, Kumada, Hiromitsu, Kaneko, Shuichi, Pracht, Marc, Mamontov, Konstantin, Meyer, Tim, Kubota, Tomoki, Dutcus, Corina E, Saito, Kenichi, Siegel, Abby B, Dubrovsky, Leonid, Mody, Kalgi, Llovet, Josep M

“…The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with…”
Get full text

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer by Kojima, Takashi, Shah, Manish A, Muro, Kei, Francois, Eric, Adenis, Antoine, Hsu, Chih-Hung, Doi, Toshihiko, Moriwaki, Toshikazu, Kim, Sung-Bae, Lee, Se-Hoon, Bennouna, Jaafar, Kato, Ken, Shen, Lin, Enzinger, Peter, Qin, Shu-Kui, Ferreira, Paula, Chen, Jia, Girotto, Gustavo, de la Fouchardiere, Christelle, Senellart, Helene, Al-Rajabi, Raed, Lordick, Florian, Wang, Ruixue, Suryawanshi, Shailaja, Bhagia, Pooja, Kang, S Peter, Metges, Jean-Philippe

“…Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. In this open-label, phase III…”
Get full text

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial by Finn, Richard S, Ryoo, Baek-Yeol, Merle, Philippe, Kudo, Masatoshi, Bouattour, Mohamed, Lim, Ho Yeong, Breder, Valeriy, Edeline, Julien, Chao, Yee, Ogasawara, Sadahisa, Yau, Thomas, Garrido, Marcelo, Chan, Stephen L, Knox, Jennifer, Daniele, Bruno, Ebbinghaus, Scot W, Chen, Erluo, Siegel, Abby B, Zhu, Andrew X, Cheng, Ann-Lii

“…Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular…”
Get full text

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50 by Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G, Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A, Riess, Jonathan W, Jensen, Erin, Zhao, Bin, Pietanza, M Catherine, Brahmer, Julie R

“…We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov…”
Get full text

First-Line Immunotherapy for Non-Small-Cell Lung Cancer by Reck, Martin, Remon, Jordi, Hellmann, Matthew D

“…For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to…”
Get full text

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update by Key, Nigel S, Khorana, Alok A, Kuderer, Nicole M, Bohlke, Kari, Lee, Agnes Y Y, Arcelus, Juan I, Wong, Sandra L, Balaban, Edward P, Flowers, Christopher R, Francis, Charles W, Gates, Leigh E, Kakkar, Ajay K, Levine, Mark N, Liebman, Howard A, Tempero, Margaret A, Lyman, Gary H, Falanga, Anna

“…To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. PubMed and the Cochrane Library…”
Get full text

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer by Gadgeel, Shirish, Rodríguez-Abreu, Delvys, Speranza, Giovanna, Esteban, Emilio, Felip, Enriqueta, Dómine, Manuel, Hui, Rina, Hochmair, Maximilian J, Clingan, Philip, Powell, Steven F, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Garon, Edward B, Novello, Silvia, Rubio-Viqueira, Belén, Boyer, Michael, Kurata, Takayasu, Gray, Jhanelle E, Yang, Jing, Bas, Tuba, Pietanza, M Catherine, Garassino, Marina C

“…In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared…”
Get full text

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial by Palma, David A, Olson, Robert, Harrow, Stephen, Gaede, Stewart, Louie, Alexander V, Haasbeek, Cornelis, Mulroy, Liam, Lock, Michael, Rodrigues, George B, Yaremko, Brian P, Schellenberg, Devin, Ahmad, Belal, Senthi, Sashendra, Swaminath, Anand, Kopek, Neil, Liu, Mitchell, Moore, Karen, Currie, Suzanne, Schlijper, Roel, Bauman, Glenn S, Laba, Joanna, Qu, X Melody, Warner, Andrew, Senan, Suresh

“…The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites…”
Get full text

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline by Korde, Larissa A, Somerfield, Mark R, Carey, Lisa A, Crews, Jennie R, Denduluri, Neelima, Hwang, E Shelley, Khan, Seema A, Loibl, Sibylle, Morris, Elizabeth A, Perez, Alejandra, Regan, Meredith M, Spears, Patricia A, Sudheendra, Preeti K, Symmans, W Fraser, Yung, Rachel L, Harvey, Brittany E, Hershman, Dawn L

“…To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. ASCO convened an Expert Panel to conduct a systematic review of…”
Get full text

Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial by Versteijne, Eva, Suker, Mustafa, Groothuis, Karin, Akkermans-Vogelaar, Janine M, Besselink, Marc G, Bonsing, Bert A, Buijsen, Jeroen, Busch, Olivier R, Creemers, Geert-Jan M, van Dam, Ronald M, Eskens, Ferry A L M, Festen, Sebastiaan, de Groot, Jan Willem B, Groot Koerkamp, Bas, de Hingh, Ignace H, Homs, Marjolein Y V, van Hooft, Jeanin E, Kerver, Emile D, Luelmo, Saskia A C, Neelis, Karen J, Nuyttens, Joost, Paardekooper, Gabriel M R M, Patijn, Gijs A, van der Sangen, Maurice J C, de Vos-Geelen, Judith, Wilmink, Johanna W, Zwinderman, Aeilko H, Punt, Cornelis J, van Eijck, Casper H, van Tienhoven, Geertjan

“…Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline resectable pancreatic cancer, but the overall benefit is…”
Get full text

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update by Allison, Kimberly H, Hammond, M Elizabeth H, Dowsett, Mitchell, McKernin, Shannon E, Carey, Lisa A, Fitzgibbons, Patrick L, Hayes, Daniel F, Lakhani, Sunil R, Chavez-MacGregor, Mariana, Perlmutter, Jane, Perou, Charles M, Regan, Meredith M, Rimm, David L, Symmans, W Fraser, Torlakovic, Emina E, Varella, Leticia, Viale, Giuseppe, Weisberg, Tracey F, McShane, Lisa M, Wolff, Antonio C

“…To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR)…”
Get full text

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up by Martin, Thomas, Usmani, Saad Z, Berdeja, Jesus G, Agha, Mounzer, Cohen, Adam D, Hari, Parameswaran, Avigan, David, Deol, Abhinav, Htut, Myo, Lesokhin, Alexander, Munshi, Nikhil C, O'Donnell, Elizabeth, Stewart, A Keith, Schecter, Jordan M, Goldberg, Jenna D, Jackson, Carolyn C, Yeh, Tzu-Min, Banerjee, Arnob, Allred, Alicia, Zudaire, Enrique, Deraedt, William, Olyslager, Yunsi, Zhou, Changwei, Pacaud, Lida, Madduri, Deepu, Jakubowiak, Andrzej, Lin, Yi, Jagannath, Sundar

“…CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with…”
Get full text

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial by Versteijne, Eva, van Dam, Jacob L, Suker, Mustafa, Janssen, Quisette P, Groothuis, Karin, Akkermans-Vogelaar, Janine M, Besselink, Marc G, Bonsing, Bert A, Buijsen, Jeroen, Busch, Olivier R, Creemers, Geert-Jan M, van Dam, Ronald M, Eskens, Ferry A L M, Festen, Sebastiaan, de Groot, Jan Willem B, Groot Koerkamp, Bas, de Hingh, Ignace H, Homs, Marjolein Y V, van Hooft, Jeanin E, Kerver, Emile D, Luelmo, Saskia A C, Neelis, Karen J, Nuyttens, Joost, Paardekooper, Gabriel M R M, Patijn, Gijs A, van der Sangen, Maurice J C, de Vos-Geelen, Judith, Wilmink, Johanna W, Zwinderman, Aeilko H, Punt, Cornelis J, van Tienhoven, Geertjan, van Eijck, Casper H J

“…The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC…”
Get full text

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline by Brahmer, Julie R, Lacchetti, Christina, Schneider, Bryan J, Atkins, Michael B, Brassil, Kelly J, Caterino, Jeffrey M, Chau, Ian, Ernstoff, Marc S, Gardner, Jennifer M, Ginex, Pamela, Hallmeyer, Sigrun, Holter Chakrabarty, Jennifer, Leighl, Natasha B, Mammen, Jennifer S, McDermott, David F, Naing, Aung, Nastoupil, Loretta J, Phillips, Tanyanika, Porter, Laura D, Puzanov, Igor, Reichner, Cristina A, Santomasso, Bianca D, Seigel, Carole, Spira, Alexander, Suarez-Almazor, Maria E, Wang, Yinghong, Weber, Jeffrey S, Wolchok, Jedd D, Thompson, John A

“…Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with…”
Get full text

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study by Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B, Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara

“…Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite…”
Get full text